Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy,

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose significant amounts of weight.